Subject: NIH Guide 071390
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Thu, 12 Jul 90 08:39 EST

Hello Paul,
Dottie's on vacation this week, so I'm downloading
the NIH Guide for her.  Hope all goes well!  Please
post to the listserver as NIHGUIDE.071390.
Thanks, Liz Pauk
 ---------------------------- Text of forwarded message -----------------------
NIH GUIDE - Vol. 19, No. 26, July 13, 1990

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

BRAIN AND TISSUE BANK FOR DEVELOPMENTAL DISORDERS (RFP) ....(84/128)......... 1
National Institute of Child Health and Human Development
Index:  CHILD HEALTH, HUMAN DEVELOPMENT

DCBDC SMALL RESEARCH GRANTS ON THE MOLECULAR AND CELLULAR BIOLOGY
OF METASTATIC TUMOR CELLS (RFA CA-90-17) ........(131/248, 324/675).......... 1
National Cancer Institute
Index:  CANCER

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

BRAIN AND TISSUE BANK FOR DEVELOPMENTAL DISORDERS
     
RFP AVAILABLE:  RFP NICHD-90-17
     
P.T. 34; K.W. 0780005, 0705010
     
National Institute of Child Health and Human Development
     
The National Institute of Child Health and Human Development (NICHD) is
planning to set up a repository to collect, store, and distribute specimens
from infants and children with neurodevelopmental disorders from both
"unaffected" (control) individuals and individuals with developmental
disorders.  The biopsy and/or autopsied tissues to be included in the brain
and tissue bank would encompass the following disorders:  diagnosed Down's
syndrome, other chromosome defects, mitochondrial encephalopathies,
phenylketonuria and other aminoacidopathies, maternal PKU, Rett syndrome,
leukodystrophies, lysosomal disorders, unexplained forms of mental
retardation, sudden infant death syndrome (SIDS), dyslexia, autism, and other
neurodevelopmental problems.  Specific tissues to be collected will include
the following:  brain, spinal cord, cerebrospinal fluid, blood and serum,
peripheral nerves, liver, kidney, pancreas, lungs, spleen, adrenal, skeletal
muscles, heart, skin, thyroid, lymph nodes, and gonads.  Tissues would be
obtained premortem, postmortem and from abortions.  These tissues will be made
available to qualified investigators to support and facilitate research that
will lead to an improved understanding of the etiology, pathology,
pathogenesis, and clinical-pathological correlation of conditions that are
associated with mental retardation, learning and behavioral deficits, and
SIDS.
     
This announcement for a brain and tissue bank is a new solicitation.  The
issuance of this RFP will be on or about August 6, 1990, and proposals are due
by 4:00pm (Local Time), October 15, 1990.  The Institute plans to make one
award from this solicitation.  Those organizations desiring a copy of the
above RFP may send their written request to:
     
Mrs. Lynn Salo
NICHD, OGC, CMS
Executive Plaza North Bldg., Rm. 515
9000 Rockville Pike
Bethesda, MD  20892
     
To receive a copy of the RFP, please supply this office with two
self-addressed mailing labels.  All responsible sources may submit a proposal
which will be considered.  This advertisement does not commit the Government
to award a contract.

DCBDC SMALL RESEARCH GRANTS ON THE MOLECULAR AND CELLULAR BIOLOGY OF
METASTATIC TUMOR CELLS
     
RFA AVAILABLE:  CA-90-17
     
P.T. 34; K.W. 1002004, 1002008, 0715035
     
National Cancer Institute
     
Letter of Intent Receipt Date:  September 10, 1990
Application Receipt Date:  October 10, 1990
     
I.  INTRODUCTION
     
The Cancer Biology Branch of the Division of Cancer Biology, Diagnosis and
Centers (DCBDC) at the National Cancer Institute (NCI) invites applications
for grants to study the molecular and cellular biology of metastatic tumor
cells.  This special initiative is designed to promote collaborations and
facilitate scientific interchange between investigators, one with experience
in the biology of metastasis and the other in a more basic scientific
discipline such as molecular or cellular biology or biochemistry.  Prospective
principal investigators are encouraged to identify a research collaborator in
order to prepare and submit a small grant application.
     
The Small Research Grants program provides limited funds (maximum of $40,000
per year) for short-term (up to 2 years) research projects.  They are
non-renewable.  Small grants provide an opportunity for initiating studies
which may be preliminary in nature.  Research investigators in relevant fields
     
             NIH GUIDE - Vol. 19, No. 26, July 13, 1990 - Page 1
are invited to apply for these grants in order to develop preliminary data
that could form the basis of future R01 or R29 applications.
     
The present Request for Applications (RFA) announcement is for a single
solicitation with a specified deadline (October 10, 1990) for receipt of
applications.  There will be up to ten awards if meritorious applications and
funds are available.
     
II.  RESEARCH GOALS AND SCOPE
     
The goal of this initiative is to provide funds for preliminary research
projects that will form the basis of future R29 and R01 applications to
investigate metastasis.  The intent is to (1) foster collaborative research
between investigators with basic molecular and cellular biological and
biochemical research experience, and those with experience in metastasis
research, and (2) increase the number of laboratories and investigators
addressing issues of metastasis.
     
The scope of the research may encompass any aspect of molecular and cellular
biology and biochemistry as they apply to metastasis biology.  Applications
should be for preliminary data gathering or pilot feasibility studies, and
should be founded on the combined research experience of the principal
investigator and his/her collaborator.  The application should specifically
address how the application meets the intent of the initiative, e.g., the
development of a new collaboration between an investigator with basic
molecular and cellular biological and biochemical research experience and one
with experience in metastasis research.  Furthermore, the research
collaborator should address how the proposed research will relate to and
integrate with other ongoing research in his/her laboratory.  Either the
principal investigator or the research collaborator must have demonstrated
experience in metastasis research.  However, the initiative is not intended
for support of applicant investigators who have such experience and propose
collaborating with laboratories that are also engaged in metastasis research
in any significant manner.  The research collaborator may collaborate with
more than one principal investigator.
     
The principal investigator must be accountable to the recipient organization
officials for the proper conduct of the project.  The research collaborator
must be named and time and effort listed on the budget page.  The recipient
organization is legally responsible and accountable to PHS for performance and
financial aspects of the grant-supported activity.
     
Just as the initiative is intended to foster a research collaboration, the
application itself should clearly be the product of in-depth discussions and
input from both the research collaborator and the principal investigator.
     
III.  MECHANISM OF SUPPORT
     
Support of this program will be through the National Institutes of Health
(NIH) grant-in-aid.  Applicants will be responsible for the planning,
direction, and execution of the proposed project.  Except as otherwise stated
in this RFA, awards will be administered under PHS policy as stated in the
Public Health Service Grants Policy statement, DHHS Publication No. (OASH)
82-50,000, revised January 1, 1987.
     
This RFA is a one-time solicitation.  Grants made under this mechanism are
non-renewable.
     
Approximately $600,000 in total costs per year for two years will be committed
to specifically fund applications which are submitted in response to this RFA.
It is anticipated that 10 awards will be made.  The total direct costs per
year must not exceed $40,000.  This funding level is dependent on the receipt
of a sufficient number of applications of high scientific merit.  The total
project period for applications submitted in response to the present RFA
should be for at least one (1) year and may not exceed two (2) years.  The
earliest feasible start date for the initial award will be March 1, 1991.
However, the award date may be delayed to as late as August 1, 1991.  Although
this program is provided for in the financial plans of the NCI, the award of
grants pursuant to this RFA is also contingent upon the availability of funds
for this purpose.
     
IV.  INQUIRIES
     
Written or telephone inquiries concerning the objectives and scope of this RFA
or inquiries about whether or not specific proposed research would be
responsive are encouraged and should be directed to Dr. Michael R. Martin at
the address below.  The Program Director welcomes the opportunity to clarify
any issues or questions from potential applicants.
     
             NIH GUIDE - Vol. 19, No. 26, July 13, 1990 - Page 2
Dr. Michael R. Martin
Program Director for Basic Cancer Biology
National Cancer Institute
Executive Plaza South, Room 630
6120 Executive Blvd.
Rockville, MD  20892
Telephone:  (301) 496-7028
Fax:  (310) 496-8656

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

             NIH GUIDE - Vol. 19, No. 26, July 13, 1990 - Page 3